Objective: The aim of this study was to examine the relationship between vitamin D levels in patients with heart failure (HF) and response to cardiac resynchronization therapy (CRT).
H eart failure (HF) is a major medical problem that is associated with significant rates of morbidity and mortality, hospitalization, and healthcare costs. Prognosis of patients remains poor despite advances in medical management. HF is also a progressive disease, involving activation of various neurohormonal systems and the sympathetic nervous system, which in the long term are responsible for pathological cardiac remodeling and disease progression. [1] Cardiac resynchronization therapy (CRT) is a valuable treatment option that is reducing both morbidity and mortality for patients with severe HF and left ventricular (LV) conduction disturbances. [2] Variety of parameters have been reported to be predictors of CRT response; however, lack of response to CRT has been reported in up to 30% to 40% of patients, necessitating novel predictors and treatment options. [3, 4] One of the biomarkers to have emerged recently is Vitamin D and its potential role in various cardiovascular disorders, including HF.
Vitamin D is a hormone that is an actor in calciumphosphorus metabolism and also has extraskeletal effects. Growing evidence suggests that vitamin D deficiency in HF is not a negligible laboratory finding and that there may be an intense association between these 2 common clinical entities. In the cardiovascular system, vitamin D regulates the renin-angiotensin aldosterone system (RAAS), inhibits vascular smooth muscle proliferation, and suppresses cardiac hypertrophy and hypercontractility. [5] Furthermore, experimental and epidemiological evidence has emphasized that vitamin D deficiency plays an important role in various cardiac diseases. [6] It was discovered that HF patients have low vitamin D concentrations, and this has been associated with poor cardiac reserve. [7] Moreover, vitamin D-deficient patients had worse LV function, and cardiovascular events were negatively affected by vitamin D level. [8] However, there was no evidence for role of vitamin D level in patients with CRT. In addition, predictive role of preimplantation vitamin D level remains unclear. Present study was an effort to determine whether vitamin D level correlates with CRT response in patients with HF.
METHODS

Study patients
Fifty-seven patients who received CRT were prospectively recruited between December 2010 and February 2011. Inclusion criteria included symptomatic New York Heart Association (NYHA) Class II or III HF, ejection fraction (EF) of <35%, and QRS duration of ≥120 milliseconds in form of bundle branch block or intraventricular conduction delay despite optimal pharmacological therapy. Following baseline characteristics were recorded: patient demographics (age and sex), QRS duration (ms), etiology of cardiomyopathy (ischemic or non-ischemic), medical history of hypertension, diabetes mellitus, current smoking, chronic obstructive pulmonary disease, atrial fibrillation (AF), and medication profile, including use of beta-blocker, angiotensin-converting enzyme inhibitor (ACEI), spironolactone, digoxin, or diuretics. Patients were excluded if they had clinical diagnosis of recent (≤30 days) acute coronary syndrome, acute decompensation of HF, revascularization procedure, or surgery. In addition, patients with hyperparathyroidism or hypercalcemia, nephrolithiasis, osteoporosis, chronic kidney disease, metastatic or advanced cancer, or current use of drugs that affect metabolism of vitamin D, such as vitamin D, corticosteroids, parathyroid hormone (PTH), androgen, or estrogen were excluded from the study. The study protocol was approved by the ethics committee, and written informed consent was obtained from all patients.
Echocardiographic examination
Serial echocardiography was performed before and after CRT implantation to assess degree of LV reverse remodeling and change in cardiac function. LV end-systolic (LVES) volume, LV end-diastolic (LVED) volume, and EF were assessed using Simpson's rule. Severity of mitral regurgitation was graded semi-quantitatively from color-flow Doppler in conventional parasternal long axis and apical 4-chamber images. Patients were classified as CRT responders if they were alive and had >15% decrease in LVES volume compared with baseline measurements.
Pacemaker implantation
LV lead was implanted in the coronary sinus in all cases to achieve permanent epicardial stimulation as previously described. [9] Final lead position was assessed using postoperative chest X-ray in anteroposterior and lateral views. Right ventricular (RV) lead was implanted in the apex in all patients. Right atrium lead was then implanted in the right atrial appendage. CRT device and lead implantations were completed without major complications. CRT devices and leads used were manufactured by Medtronic, Inc. (Minneapolis, MN, USA) and Biotronik SE & Co. KG (Berlin, Germany). Devices were programmed with pacing mode DDD to maximize biventricular pacing. Re-evaluation of coronary-sinus lead position, pacing mode, and programming of timing intervals was performed 1, 3, and 6 months after implantation.
25-hydroxy vitamin D measurement
Level of 25-hydroxy (OH) vitamin D was measured using enzyme-linked immunosorbent assay test kits (DRG Diagnostics GmbH, Marburg, Germany) with dynamic range of 2.9-130 ng/mL. Intra-and interassay precision were 4.7% and 10.2 %, respectively.
Statistical analysis
Statistical analyses were performed using SPSS statistical software, version 20 (IBM Corp., Armonk, NY, USA). All variables were examined with regard to distributional properties using Shapiro-Wilk test, visual inspection, and assessment of kurtosis and skew. Normally distributed continuous variables were analyzed using Student's t-test and expressed as mean±SD. Abnormally distributed continuous variables were analyzed using Mann-Whitney U test and expressed as median (min-max). Categorical variables were presented as percentages and analyzed using chi-square test or Fisher's exact test. Univariate analysis of baseline variables was performed initially to investigate association between covariates and incidence of non-responders. Then, multivariate analysis (backward logistic regression) was performed using variables with p value ≤0.25 in univariate analysis. P value <0.05 was considered statistically significant.
RESULTS
Patient characteristics
Total of 57 patients (median age: 62 years [range: 23-83 years]; 66.7% men) who were referred to center for CRT device implantation were enrolled in the study. All patients received biventricular implantable cardioverter defibrillator. There was no difference in age, gender, risk factors, or echocardiographic features (EF, end-systolic volume, or mitral regurgitation). There were significant differences in QRS morphology. Left bundle branch block morphology was more frequently seen in responder group (p=0.031).
Sinus rhythm was present in 53 cases, chronic AF in 4 patients, and QRS duration ranged from 120 to 230 milliseconds (mean: 160±25.3 ms). LV lead was implanted in lateral-posterolateral (n=50) or anterolateral (n=7) branch of cardiac venous system. The RV lead was implanted at RV apex in all patients. Baseline characteristics of the study population are provided in Table 1 .
Follow-up
After CRT implantation, QRS shortening was significantly greater among responders than non-responders (22±21 ms vs 9±14 ms; p=0.014). Improvement in NYHA class >1 was also more common in responders than non-responders (73.5% vs 30.4%; p<0.001). In addition to clinical improvement, significant LV reverse remodeling was only observed in responder group, with mean decrease in LVES volume from 130 mL (range: 81-248 mL) to 107 mL (range: 40-213 mL) (p<0.001), and mean increase in EF from 27.3±5.4% at baseline to 35.3±7.8% at 6-month follow-up (p<0.001). There was significant worsening in cardiac dimensions and systolic function in nonresponder group: LVES volume increase from 130 mL (range: 81-248 mL) to 135 mL (range: 71-260 mL) (p=0.510) and EF change from 26.7±23% to 27.3±3.8% (p=0.695).
Vitamin D and predictors of response to cardiac resynchronization therapy
Mean vitamin D level was 24.2±7.20 ng/dL and medial B-type natriuretic peptide (BNP) level was 347 pg/mL (range: 100-1825 pg/mL of vitamin D and worsening left ventricular function and disease severity. [10] [11] [12] Liu et al. reported that lower vitamin D levels were associated with higher level of BNP and higher plasma renin activity (PRA), as well as increased HF hospitalization and overall higher incidence of all-cause mortality. In this study, low level of vitamin D was identified as independent risk factor for HF hospitalization and mortality. [13] Potential benefit of vitamin D supplementation in patients with HF has been an area of significant research interest. sis in the myocardium and vessel wall. This in turn leads to fibrosis and chamber remodeling. [18] It was discovered that stimulation of collagen synthesis and deposition may account for negative response to CRT. [19] There was no decrease in collagen synthesis in nonresponder patients. RAAS activation due to low level of vitamin D may prevent reverse remodeling effect of CRT. Low levels of vitamin D may contribute to the pro-inflammatory status in patients with HF, and may therefore play an important role in response to CRT. [13] Numerous reports have noted that CRT decreases inflammatory status of HF patients. In non-responder patients, markers related to inflammation do not decrease after CRT implantation. Low level of vitamin D may be associated with anti-inflammatory effect of CRT and decrease response to this therapy. Despite these possible explanations, it is unclear whether low levels of vitamin D are only a marker of response to CRT or an important factor to promote CRT response.
The main limitation of our study was small sample size, but this was the first study to evaluate role of vitamin D in CRT response. In addition, current guidelines include Class I recommendation for CRT in patients with QRS duration ≥150 ms. Only two-thirds of the patients in present study met this criterion. Finally, use of more rigorous methods than ELISA test will yield more accurate results.
Conclusion
In summary, to the best of our knowledge, this is the first study to show predictive value of vitamin D in CRT response. Although based upon limited number of patients, preimplantation vitamin D levels independently predicted CRT response. Therefore, assessment of vitamin D status appears useful before CRT implantation. The results of our study deserve further research. New studies that examine effect of vitamin D supplementation prior to implantation on CRT response with more patients would be useful.
Moreover, it has been determined that in patients with HF, vitamin D supplementation may reduce disease progression and symptom severity through suppression of RAAS and PTH, down-regulation of inflammatory mediators, suppression of cardiac remodeling, promotion of cell growth and differentiation, reduction of blood pressure, and improvement in muscle strength. [14] However, studies have reported contradictory results, and some results were disappointing. Further large-scale randomized multicenter studies are needed to support role of routine vitamin D supplementation as part of clinical care for patients who underwent CHF.
Despite several studies demonstrating relationship between level of vitamin D and HF, exact mechanism by which vitamin D deficiency leads to poor clinical outcome has not been clearly established. Recently, growing evidence on pathophysiology of HF has shown that complex correlations between inflammatory cytokines, neurohormones, and vitamin D have an important role. Animal studies indicated that vitamin D inhibits RAAS, which then contributes to the salt and water retention seen in HF. [5] Overactivation of RAAS has also been reported in HF patients with vitamin D deficiency, and blockade of this system serves as cornerstone of medical management of HF. [6, 13] In addition, vitamin D has a number of effects that should help prevent hypertension, an important risk factor for HF. [15] Precise link between vitamin D deficiency and poor response to CRT is not yet known. Vitamin D plays important physiological role in controlling cardiac functions, and vitamin D-dependent signaling pathways are present in cardiac myocytes. [16] In animal studies, histological staining of cardiac tissue showed highly significant cellular hypertrophy and collagen deposition in vitamin D receptor knockout mice compared to wild-type mice. Vitamin D modulates myocardial extracellular matrix turnover acting on expression of both matrix metalloproteinases (MMPs), which hydrolyze extracellular matrix proteins, and tissue inhibitors of metalloproteinases (TIMPs). In vitamin D receptor knockout mice, unbalanced MMP/TIMP expression was associated with myocardial fibrosis and hypertrophy. [17] In addition, low levels of vitamin D have been shown to be inversely related to PRA. This results in increased level of aldosterone, which induces hypertrophy and dysregulation of proliferation and apopto-
